Spots Global Cancer Trial Database for advanced breast cancer
Every month we try and update this database with for advanced breast cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| RCT of CBD for Anxiety in Advanced Breast Cancer | NCT04482244 | Advanced Breast... Anxiety CBD | Cannabidiol Placebo | 18 Years - | Dana-Farber Cancer Institute | |
| HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer | NCT00719875 | Advanced Breast... | Vorinostat | 18 Years - | Yale University | |
| Clinical Study of Decitabine and Paclitaxel Combination Therapy | NCT03282825 | Advanced Breast... | Decitabine Paclitaxel | 19 Years - | Dong Wha Pharmaceutical Co. Ltd. | |
| Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd | NCT06298084 | Breast Cancer M... HER2-positive M... HER2 Low Breast... Advanced Breast... | Patritumab deru... Olaparib | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| A Nation-wide Multicenter Clinical Epidemiologic Study of Chinese Females With Advanced Breast | NCT03047889 | Advanced Breast... | standard therap... | 18 Years - 99 Years | ChineseAMS | |
| Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC | NCT05191004 | Advanced Breast... Metastatic Brea... Breast Cancer Breast Carcinom... Cancer of the B... Cancer of Breas... Malignant Tumor... Breast Tumor | NUV-422 Fulvestrant | 18 Years - | Nuvation Bio Inc. | |
| CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) | NCT02580448 | Cancer of the B... Breast Cancer Advanced Breast... Metastatic Brea... Male Breast Can... Triple Negative... ER+ Breast Canc... | Seviteronel | 18 Years - | Innocrin Pharmaceutical | |
| HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer | NCT03685331 | Metastatic Brea... Locally Advance... Advanced Breast... BRCA2 Mutation BRCA1 Mutation | Palbociclib Olaparib Fulvestrant | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis | NCT05431504 | Advanced Breast... | Dalpiciclib in ... | 18 Years - | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| A Study of LXI-15029 in Patients With Advanced Malignant Solid Tumors | NCT03125746 | Advanced Breast... | LXI-15029 LXI-15029+Exeme... | 18 Years - 65 Years | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | |
| Real-world Treatment Patterns of Endocrine Based Therapy Among Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor-2-negative (HR+/HER2-) Advanced Breast Cancer: An Analysis of Administrative Claims Data in Japan | NCT05153187 | Breast Cancer | - | Pfizer | ||
| A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer | NCT05584644 | Breast Cancer Breast Carcinom... Breast Neoplasm... Breast Tumors Cancer of Breas... | Palbociclib plu... Palbociclib plu... | 18 Years - 99 Years | Pfizer | |
| Phase II Dasatinib Study in Advanced Breast Cancer | NCT00546104 | Advanced Breast... | Dasatinib | 18 Years - | Duke University | |
| Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus Zoladex | NCT00235937 | Breast Cancer | Anastrozole and... | 18 Years - | AstraZeneca | |
| Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women | NCT01300351 | Breast Cancer | Fulvestrant Placebo | 18 Years - | AstraZeneca | |
| TAS-116 Plus Palbociclib in Breast and Rb-null Cancer | NCT05655598 | Advanced Breast... Treatment-Refra... Retinoblastoma ... SCLC Soft Tissue Sar... Endometrial Can... Bladder Cancer | Palbociclib Ora... TAS-116 TAS-116 TAS-116 | 18 Years - | Brown University | |
| First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer | NCT05216432 | PIK3CA Mutation Solid Tumor, Ad... HER2-negative B... Breast Cancer Metastatic Brea... Advanced Breast... Unresectable So... | RLY-2608 Fulvestrant Palbociclib 125... Ribociclib 400m... Ribociclib 600m... | 18 Years - | Relay Therapeutics, Inc. | |
| Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC | NCT02140437 | Carcinoma Breas... | Fulvestrant Anastrozole | 18 Years - 80 Years | Fudan University | |
| Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer | NCT01875367 | Breast Cancer | Trastuzumab Inj... Trastuzumab Inj... Trastuzumab Inj... | 18 Years - | Spanish Breast Cancer Research Group | |
| Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer | NCT04756765 | Breast Cancer Advanced Breast... | Talazoparib Tos... | 18 Years - | Stanford University | |
| A Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast Cancer During or Following Chemotherapy | NCT00109265 | Breast Cancer | Erlotinib HCl (... | 18 Years - | Genentech, Inc. | |
| Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors | NCT04541225 | Glioma Glioma, Maligna... Glioma, Mixed Glial Cell Tumo... Breast Cancer Breast Carcinom... Cancer of Breas... Cancer of the B... Breast Tumor Malignant Tumor... Advanced Breast... Advanced Breast... Metastatic Brea... Metastatic Brea... Prostate Cancer Prostatic Cance... Cancer of Prost... Cancer of the P... Prostate Neopla... Castrate Resist... Castration-resi... Castration Resi... Glioblastoma Recurrent Gliob... | NUV-422 | 18 Years - | Nuvation Bio Inc. | |
| Halaven Patient Registry (Metastatic Breast Cancer, MBC) | NCT03245112 | Metastatic Brea... Advanced Breast... | Eribulin Mesyla... | 24 Years - 85 Years | Chang Gung Memorial Hospital | |
| Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer | NCT00093145 | Breast Cancer | Albumin-bound p... Carboplatin Herceptin® | 18 Years - | Celgene | |
| Safety and Pharmacokinetics of ODM-209 | NCT03878823 | Prostate Cancer... Advanced Breast... Castration-resi... Metastatic Brea... | ODM-209 | 18 Years - | Orion Corporation, Orion Pharma | |
| To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy | NCT02549430 | Breast Cancer | Palbociclib Anastrozole Letrozole Exemestane Fulvestrant | 18 Years - | Fondazione Sandro Pitigliani | |
| STRIDE - STimulating Immune Response In aDvanced brEast Cancer | NCT00925548 | Breast Cancer | Tecemotide (L-B... Placebo of tece... cyclophosphamid... sodium chloride... | 18 Years - | EMD Serono | |
| A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer | NCT06075810 | Breast Cancer Breast Neoplasm Breast Cancer S... | MBQ-167 | 21 Years - | MBQ Pharma | |
| The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial | NCT03182634 | Advanced Breast... | Fulvestrant Neratinib AZD5363 Olaparib AZD6738 | 18 Years - | Institute of Cancer Research, United Kingdom | |
| Non-interventional Study to Evaluate Arimidex in Postmenopausal Women With Advanced Breast Cancer | NCT00562458 | Advanced Breast... | anastrozole | - | AstraZeneca | |
| PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin | NCT05810870 | Breast Cancer Advanced Breast... Metastatic Brea... | MEN1611 Eribulin | 18 Years - | MedSIR | |
| A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg | NCT00305448 | Advanced Breast... Metastatic Brea... | Fulvestrant Fulvestrant | - | AstraZeneca | |
| Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer | NCT02910050 | Breast Cancer | Bicalutamide Aromatase Inhib... | 18 Years - 80 Years | Sun Yat-sen University | |
| Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer | NCT04524000 | Advanced Breast... | Alpelisib Fulvestrant | 18 Years - | Novartis | |
| Guardant360® Related Clinical Outcomes in Patients Who Share Medical Records-Breast Cancer | NCT04436393 | Advanced Breast... | Guardant360 tes... | 18 Years - | Guardant Health, Inc. | |
| A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer | NCT05775575 | Advanced Breast... | TQB3909 tablets | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7) | NCT04227327 | Advanced Breast... | Abemaciclib Aromatase Inhib... | 18 Years - | University of Milano Bicocca | |
| Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer | NCT02069093 | Advanced Breast... | Dexamethasone b... Everolimus Exemestane | 18 Years - | Novartis | |
| Cambridge Brain Mets Trial 1 | NCT02768337 | Lung Cancer Breast Cancer Brain Cancer Advanced Breast... Advanced Lung C... | Afatinib 2 Gy targeted r... 4 Gy targeted r... | 18 Years - | Cambridge University Hospitals NHS Foundation Trust | |
| A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg | NCT00313170 | Advanced Breast... Metastatic Brea... | Fulvestrant | 45 Years - 130 Years | AstraZeneca | |
| PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer | NCT05812326 | Advanced Breast... Breast Neoplasm... | AJMUC1- PD-1 ge... | 18 Years - 70 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer. | NCT05439499 | Advanced Breast... Female Breast C... | FCN-437c, Letro... Placebo, Letroz... | 18 Years - | Ahon Pharmaceutical Co., Ltd. | |
| Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy | NCT06125834 | Advanced Breast... Objective Respo... Trastuzumab Emt... | Trastuzumab Emt... | 18 Years - 70 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Neoadjuvant Herceptin in Patients With Breast Cancer | NCT00133796 | BREAST CANCER | Herceptin | 18 Years - 90 Years | Baylor Breast Care Center | |
| OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | NCT06016738 | Breast Cancer Advanced Breast... Metastatic Brea... ER Positive Bre... HER2 Negative B... | Palazestrant Fulvestrant Anastrozole Letrozole Exemestane | 18 Years - | Olema Pharmaceuticals, Inc. | |
| AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer. | NCT00454805 | Advanced Breast... | AZD2171 Fulvestrant | 18 Years - 130 Years | AstraZeneca | |
| Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor | NCT05536128 | Advanced Breast... | Olaparib Fulvestrant | 19 Years - | Seoul National University Hospital | |
| PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer | NCT05812326 | Advanced Breast... Breast Neoplasm... | AJMUC1- PD-1 ge... | 18 Years - 70 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy. | NCT00099437 | Breast Cancer | Fulvestrant | 45 Years - 130 Years | AstraZeneca | |
| A Phase I Study of LX-039 Tablets | NCT04097756 | Advanced Breast... | LX-039 tablets | 18 Years - 75 Years | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | |
| The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis | NCT05431504 | Advanced Breast... | Dalpiciclib in ... | 18 Years - | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer | NCT06123988 | HER2-positive B... Advanced Breast... | Prolonged Overn... Moderate-Intens... General Health ... | 18 Years - | University of Miami | |
| Developing Plasma DNA as a Surrogate for Tumor Biopsy to Identify Tumor Genetic Alterations in Patients With Advanced Breast Cancer | NCT01836640 | Advanced Breast... | 18 Years - 99 Years | Dartmouth-Hitchcock Medical Center | ||
| Capecitabine + Bendamustine in Women With Pretreated Locally Advanced or Metastatic Her2-negative Breast Cancer | NCT01891227 | Breast Cancer | Capecitabine Bendamustine | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer | NCT05504213 | Breast Cancer | HS-10352 combin... HS-10352 combin... | 18 Years - | Jiangsu Hansoh Pharmaceutical Co., Ltd. | |
| Developing Plasma DNA as a Surrogate for Tumor Biopsy to Identify Tumor Genetic Alterations in Patients With Advanced Breast Cancer | NCT01836640 | Advanced Breast... | 18 Years - 99 Years | Dartmouth-Hitchcock Medical Center | ||
| Dalpiciclib in HR+/HER2- ABC | NCT06301438 | Advanced Breast... | dalpiciclib | 18 Years - | RenJi Hospital | |
| Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer | NCT06433609 | Advanced Breast... | SHR-A1811 SHR-A1921 Adebrelimab | 18 Years - 75 Years | Beijing GoBroad Hospital | |
| A Study Comparing Immunopheresis® Alone or In Combination With Chemotherapy Versus Chemotherapy Alone in Treatment of Advanced Breast Cancer Patients | NCT04004910 | Advanced Breast... | Plasma soluble ... Plasma soluble ... Chemotherapy Dr... | 18 Years - | Immunicom Inc | |
| Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors | NCT04222413 | Advanced Solid ... Metastatic Panc... Pediatric Solid... Advanced Breast... Malignant Perip... Colorectal Neop... | Metarrestin | 12 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC | NCT02140437 | Carcinoma Breas... | Fulvestrant Anastrozole | 18 Years - 80 Years | Fudan University | |
| Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer | NCT00052169 | Breast Neoplasm... | ZD1839 in combi... | 18 Years - | NSABP Foundation Inc | |
| Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer | NCT00393939 | Breast Neoplasm... | Sunitinib malat... Taxotere | 18 Years - | Pfizer | |
| The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC). | NCT06217185 | HER2-positive B... Advanced Breast... | Pyrotinib Trastuzumab Taxanes Capecitabine | 18 Years - 70 Years | Hebei Medical University Fourth Hospital | |
| This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer. | NCT05438810 | Advanced Breast... Female Breast C... | FCN-437c,Fulves... Placebo,Fulvest... | 18 Years - | Ahon Pharmaceutical Co., Ltd. | |
| Second Line Breast Cancer Trial | NCT00635713 | Advanced Breast... | Fulvestrant Anastrozole Fulvestrant | 18 Years - | AstraZeneca | |
| Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. | NCT02437318 | Breast Cancer | Fulvestrant Alpelisib Alpelisib place... | 18 Years - | Novartis | |
| Clinical Study of Decitabine and Paclitaxel Combination Therapy | NCT03282825 | Advanced Breast... | Decitabine Paclitaxel | 19 Years - | Dong Wha Pharmaceutical Co. Ltd. | |
| HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer | NCT00719875 | Advanced Breast... | Vorinostat | 18 Years - | Yale University | |
| Palbociclib in Real World Practice | NCT03280303 | Advanced Breast... Metastatic Brea... | non-interventio... | 18 Years - | Pfizer | |
| Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib | NCT05020964 | Advanced Breast... | Trastuzumab and... | 18 Years - 75 Years | ChineseAMS | |
| A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer | NCT03811418 | Advanced Breast... HER2-positive B... | Trastuzumab Pertuzumab Vinorelbine Docetaxel | 18 Years - | iOMEDICO AG | |
| BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors | NCT06120283 | Advanced Solid ... Advanced Breast... Metastatic Brea... Hormone-recepto... Hormone Recepto... Hormone Recepto... HER2-negative B... Hormone Recepto... Non-small Cell ... | BGB-43395 Fulvestrant Letrozole | 18 Years - | BeiGene | |
| Phase II Dasatinib Study in Advanced Breast Cancer | NCT00546104 | Advanced Breast... | Dasatinib | 18 Years - | Duke University | |
| Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer | NCT02657889 | Neoplasms Triple Negative... Ovarian Cancer Breast Cancer Metastatic Brea... Advanced Breast... Stage IV Breast... Fallopian Tube ... Peritoneal Canc... | niraparib pembrolizumab | 18 Years - | Tesaro, Inc. | |
| Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer | NCT03205761 | Advanced Breast... | Olaparib | 18 Years - | Spanish Breast Cancer Research Group | |
| A Study of LXI-15029 in Patients With Advanced Malignant Solid Tumors | NCT03125746 | Advanced Breast... | LXI-15029 LXI-15029+Exeme... | 18 Years - 65 Years | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | |
| Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer | NCT05227131 | Metastatic Brea... Advanced Breast... HER2-positive B... | Margetuximab Tucatinib Capecitabine | 18 Years - 100 Years | MedSIR | |
| A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer | NCT03966898 | Advanced Breast... | SHR6390 Tablets Placebo Tablets Letrozole or An... | 18 Years - 75 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| A Pharmacokinetic Comparison Study of SYHX2011 and Abraxane® in Patients With Advanced Breast Cancer | NCT05274893 | Advanced Breast... | SYHX2011 and Ab... | 18 Years - 75 Years | CSPC Ouyi Pharmaceutical Co., Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
